Monte Rosa Therapeutics, Inc. GLUE Accrued expenses and other liabilities
Accrued expenses and other liabilities at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s accrued expenses and other liabilities?
- Monte Rosa Therapeutics, Inc. (GLUE) reported accrued expenses and other liabilities of -$3.71M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s accrued expenses and other liabilities changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s accrued expenses and other liabilities decreased by 42.4% year-over-year, from -$2.61M to -$3.71M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s accrued expenses and other liabilities?
- Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s accrued expenses and other liabilities has grown at a 5.3% compound annual growth rate (CAGR), from $6.73M to $7.85M.